Literature DB >> 15297452

Transcriptional regulation of APOBEC3G, a cytidine deaminase that hypermutates human immunodeficiency virus.

Kristine M Rose1, Mariana Marin, Susan L Kozak, David Kabat.   

Abstract

Apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G (APOBEC3G) is an antiretroviral deoxycytidine deaminase that lethally hypermutates human immunodeficiency virus type 1 (HIV-1) but is itself neutralized by the HIV-1-encoded viral infectivity factor. Accordingly, APOBEC3G occurs specifically in human T lymphocytic cell lines that contain this antiviral defense, including H9. Since the substrate specificities of related cytidine deaminases are strongly influenced by their intracellular quantities, we analyzed the factors that control APOBEC3G expression. The levels of APOBEC3G mRNA and protein were unaffected by treatment of proliferating H9 cells with interferons or tumor necrosis factor-alpha but were enhanced up to 20-fold by phorbol myristate acetate. This induction was mediated at the transcriptional level by a pathway that required activation of the protein kinase Calpha/betaI isozyme (PKC), mitogen-activated protein kinase kinase (MEK) 1 and 2, and extracellular signal-regulated kinase (ERK). Correspondingly, induction of APOBEC3G was blocked by multiple inhibitors that act at diverse steps of this pathway. The PKCalpha/betaI/MEK/ERK pathway also controlled basal levels of APOBEC3G mRNA and protein, which consequently declined when cells were treated with these inhibitors or arrested in the G(0) state of the cell cycle by serum starvation. We conclude that expression of the antiviral APOBEC3G editing enzyme is dynamically controlled by the PKCalpha/betaI/MEK/ERK protein kinase cascade in human T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15297452     DOI: 10.1074/jbc.M406760200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  39 in total

1.  APOBEC3 proteins and genomic stability: the high cost of a good defense.

Authors:  Iñigo Narvaiza; Sébastien Landry; Matthew D Weitzman
Journal:  Cell Cycle       Date:  2012-01-01       Impact factor: 4.534

2.  NFAT and IRF proteins regulate transcription of the anti-HIV gene, APOBEC3G.

Authors:  Melissa A Farrow; Eun-Young Kim; Steven M Wolinsky; Ann M Sheehy
Journal:  J Biol Chem       Date:  2010-11-15       Impact factor: 5.157

3.  Vif substitution enables persistent infection of pig-tailed macaques by human immunodeficiency virus type 1.

Authors:  Rajesh Thippeshappa; Patricia Polacino; Monica T Yu Kimata; Edward B Siwak; David Anderson; Weiming Wang; Laura Sherwood; Reetakshi Arora; Michael Wen; Paul Zhou; Shiu-Lok Hu; Jason T Kimata
Journal:  J Virol       Date:  2011-02-02       Impact factor: 5.103

4.  Innate antiviral response targets HIV-1 release by the induction of ubiquitin-like protein ISG15.

Authors:  Atsushi Okumura; Gengshi Lu; Ian Pitha-Rowe; Paula M Pitha
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-24       Impact factor: 11.205

Review 5.  Multiple APOBEC3 restriction factors for HIV-1 and one Vif to rule them all.

Authors:  Belete A Desimmie; Krista A Delviks-Frankenberrry; Ryan C Burdick; DongFei Qi; Taisuke Izumi; Vinay K Pathak
Journal:  J Mol Biol       Date:  2013-11-02       Impact factor: 5.469

6.  Elucidation of the time course of adenosine deaminase APOBEC3G and viral infectivity factor vif in HIV-2(287) -infected infant macaques.

Authors:  Aaron N Endsley; Rodney J Y Ho
Journal:  J Med Primatol       Date:  2011-10-24       Impact factor: 0.667

7.  Differential requirements for HIV-1 Vif-mediated APOBEC3G degradation and RUNX1-mediated transcription by core binding factor beta.

Authors:  Juan Du; Ke Zhao; Yajuan Rui; Peng Li; Xiaohong Zhou; Wenyan Zhang; Xiao-Fang Yu
Journal:  J Virol       Date:  2012-11-21       Impact factor: 5.103

8.  Sole copy of Z2-type human cytidine deaminase APOBEC3H has inhibitory activity against retrotransposons and HIV-1.

Authors:  Lindi Tan; Phuong Thi Nguyen Sarkis; Tao Wang; Chunjuan Tian; Xiao-Fang Yu
Journal:  FASEB J       Date:  2008-09-30       Impact factor: 5.191

9.  Regulation of Vif mRNA splicing by human immunodeficiency virus type 1 requires 5' splice site D2 and an exonic splicing enhancer to counteract cellular restriction factor APOBEC3G.

Authors:  Dibyakanti Mandal; Colin M Exline; Zehua Feng; C Martin Stoltzfus
Journal:  J Virol       Date:  2009-04-08       Impact factor: 5.103

10.  IFN-α treatment inhibits acute Friend retrovirus replication primarily through the antiviral effector molecule Apobec3.

Authors:  Michael S Harper; Bradley S Barrett; Diana S Smith; Sam X Li; Kathrin Gibbert; Ulf Dittmer; Kim J Hasenkrug; Mario L Santiago
Journal:  J Immunol       Date:  2013-01-11       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.